Functions of γC cytokines in immune homeostasis: Current and potential clinical applications

Clinical Immunology

Volumn 132, Issue 2, 2009, Pages 153-165

  Overwijk, Willem W ^a   Schluns, Kimberly S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adoptive cell therapy; Common gamma chain; Cytokine therapy; Human immunodeficiency virus; Immune reconstitution; Lymphocyte homeostasis; Lymphopenia induced proliferation; Regulatory T cells; Tumor infiltrating lymphocytes

Indexed keywords

CYTOKINE RECEPTOR AGONIST; GLYCOPROTEIN GP 100; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MELAN A; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 21; RECOMBINANT INTERLEUKIN 7; UNCLASSIFIED DRUG; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR;

ADOPTIVE TRANSFER; CELL THERAPY; CLINICAL TRIAL; DRUG MEGADOSE; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; IMMUNOLOGY; METABOLISM; REVIEW; T LYMPHOCYTE;

ANIMALS; HOMEOSTASIS; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-7; INTERLEUKINS; MODELS, BIOLOGICAL; RECEPTORS, INTERLEUKIN; T-LYMPHOCYTES;

EID: 67649976634     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.03.512     Document Type: Short Survey

References (94)

1. Boyman O., Surh C.D., and Sprent J. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert. Opin. Biol. Ther. 6 (2006) 1323-1331
2. Fontenot J.D., Dooley J.L., Farr A.G., and Rudensky A.Y. Developmental regulation of Foxp3 expression during ontogeny. J. Exp. Med. 202 (2005) 901-906
3. Emery S., Capra W.B., Cooper D.A., Mitsuyasu R.T., Kovacs J.A., Vig P., Smolskis M., Saravolatz L.D., Lane H.C., Fyfe G.A., and Curtin P.T. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J. Infect. Dis. 182 (2000) 428-434
4. Marchetti G., Meroni L., Varchetta S., Terzieva V., Bandera A., Manganaro D., Molteni C., Trabattoni D., Fossati S., Clerici M., Galli M., Moroni M., Franzetti F., and Gori A. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J. Infect. Dis. 186 (2002) 606-616
5. Kovacs J.A., Lempicki R.A., Sidorov I.A., Adelsberger J.W., Sereti I., Sachau W., Kelly G., Metcalf J.A., Davey Jr. R.T., Falloon J., Polis M.A., Tavel J., Stevens R., Lambert L., Hosack D.A., Bosche M., Issaq H.J., Fox S.D., Leitman S., Baseler M.W., Masur H., Di Mascio M., Dimitrov D.S., and Lane H.C. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J. Clin. Invest. 115 (2005) 2139-2148
6. Sereti I., Imamichi H., Natarajan V., Imamichi T., Ramchandani M.S., Badralmaa Y., Berg S.C., Metcalf J.A., Hahn B.K., Shen J.M., Powers A., Davey R.T., Kovacs J.A., Shevach E.M., and Lane H.C. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J. Clin. Invest. 115 (2005) 1839-1847
7. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13 (1995) 688-696
8. Rosenstein M., Ettinghausen S.E., and Rosenberg S.A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol. 137 (1986) 1735-1742
9. Yang J.C., Sherry R.M., Steinberg S.M., Topalian S.L., Schwartzentruber D.J., Hwu P., Seipp C.A., Rogers-Freezer L., Morton K.E., White D.E., Liewehr D.J., Merino M.J., and Rosenberg S.A. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21 (2003) 3127-3132
10. Cotran R.S., Pober J.S., Gimbrone Jr. M.A., Springer T.A., Wiebke E.A., Gaspari A.A., Rosenberg S.A., and Lotze M.T. Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J. Immunol. 140 (1988) 1883-1888
11. Kornfeld H., Berman J.S., Beer D.J., and Center D.M. Induction of human T lymphocyte motility by interleukin 2. J. Immunol. 134 (1985) 3887-3890
12. Vyth-Dreese F.A., Dellemijn T.A., Frijhoff A., van K.Y., and Figdor C.G. Role of LFA-1/ICAM-1 in interleukin-2-stimulated lymphocyte proliferation. Eur. J. Immunol. 23 (1993) 3292-3299
13. Gately M.K., Anderson T.D., and Hayes T.J. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. J. Immunol. 141 (1988) 189-200
14. Lenardo M.J. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 353 (1991) 858-861
15. Weninger W., Crowley M.A., Manjunath N., and von Andrian U.H. Migratory properties of naive, effector, and memory CD8(+) T cells. J. Exp. Med. 194 (2001) 953-966
16. Zhang H., Chua K.S., Guimond M., Kapoor V., Brown M.V., Fleisher T.A., Long L.M., Bernstein D., Hill B.J., Douek D.C., Berzofsky J.A., Carter C.S., Read E.J., Helman L.J., and Mackall C.L. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat. Med. 11 (2005) 1238-1243
17. Ahmadzadeh M., and Rosenberg S.A. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107 (2006) 2409-2414
18. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., Dellemijn T.A., Antony P.A., Spiess P.J., Palmer D.C., Heimann D.M., Klebanoff C.A., Yu Z., Hwang L.N., Feigenbaum L., Kruisbeek A.M., Rosenberg S.A., and Restifo N.P. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198 (2003) 569-580
19. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., and White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4 (1998) 321-327
20. Smith F.O., Downey S.G., Klapper J.A., Yang J.C., Sherry R.M., Royal R.E., Kammula U.S., Hughes M.S., Restifo N.P., Levy C.L., White D.E., Steinberg S.M., and Rosenberg S.A. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 14 (2008) 5610-5618
21. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Sznol M., Schwarz S.L., Spiess P.J., Wunderlich J.R., Seipp C.A., Einhorn J.H., Rogers-Freezer L., and White D.E. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163 (1999) 1690-1695
22. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., Rogers L.J., Gracia G.J., Jones S.A., Mangiameli D.P., Pelletier M.M., Gea-Banacloche J., Robinson M.R., Berman D.M., Filie A.C., Abati A., and Rosenberg S.A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin.Oncol. 23 (2005) 2346-2357
23. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., and Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26 (2008) 5233-5239
24. Zhou J., Shen X., Huang J., Hodes R.J., Rosenberg S.A., and Robbins P.F. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175 (2005) 7046-7052
25. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., and Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333 (1995) 1038-1044
26. Bollard C.M., Kuehnle I., Leen A., Rooney C.M., and Heslop H.E. Adoptive immunotherapy for posttransplantation viral infections. Biol. Blood Marrow Transplant. 10 (2004) 143-155
27. Joseph A., Zheng J.H., Follenzi A., Dilorenzo T., Sango K., Hyman J., Chen K., Piechocka-Trocha A., Brander C., Hooijberg E., Vignali D.A., Walker B.D., and Goldstein H. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J. Virol. 82 (2008) 3078-3089
28. van Lunzen J., Glaunsinger T., Stahmer I., von B.V., Baum C., Schilz A., Kuehlcke K., Naundorf S., Martinius H., Hermann F., Giroglou T., Newrzela S., Muller I., Brauer F., Brandenburg G., Alexandrov A., and von Laer D. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol. Ther. 15 (2007) 1024-1033
29. Masteller E.L., Tang Q., and Bluestone J.A. Antigen-specific regulatory T cells-ex vivo expansion and therapeutic potential. Semin. Immunol. 18 (2006) 103-110
30. Roncarolo M.G., and Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 7 (2007) 585-598
31. Allan S.E., Broady R., Gregori S., Himmel M.E., Locke N., Roncarolo M.G., Bacchetta R., and Levings M.K. CD4+ T-regulatory cells: toward therapy for human diseases. Immunol. Rev. 223 (2008) 391-421
32. Freeden-Jeffry U., Vieira P., Lucian L.A., McNeil T., Burdach S.E., and Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 181 (1995) 1519-1526
33. Peschon J.J., Morrissey P.J., Grabstein K.H., Ramsdell F.J., Maraskovsky E., Gliniak B.C., Park L.S., Ziegler S.F., Williams D.E., Ware C.B., Meyer J.D., and Davison B.L. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 180 (1994) 1955-1960
34. Schluns K.S., Kieper W.C., Jameson S.C., and Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 1 (2000) 426-432
35. Goldrath A.W., Sivakumar P.V., Glaccum M., Kennedy M.K., Bevan M.J., Benoist C., Mathis D., and Butz E.A. Cytokine requirements for acute and basal homeostatic proliferation of naive and memory CD8+ T cells. J. Exp. Med. 195 (2002) 1515-1522
36. Rocha B., Dautigny N., and Pereira P. Peripheral T lymphocytes: expansion potential and homeostatic regulation of pool sizes and CD4/CD8 ratios in vivo. Eur. J. Immunol. 19 (1989) 905-911
37. Goldrath A.W., and Bevan M.J. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity 11 (1999) 183-190
38. Swainson L., Verhoeyen E., Cosset F.L., and Taylor N. IL-7R alpha gene expression is inversely correlated with cell cycle progression in IL-7-stimulated T lymphocytes. J. Immunol. 176 (2006) 6702-6708
39. Brady J., Hayakawa Y., Smyth M.J., and Nutt S.L. IL-21 induces the functional maturation of murine NK cells. J. Immunol. 172 (2004) 2048-2058
40. Banham A.H. Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. Trends Immunol. 27 (2006) 541-544
41. Rosenberg S.A., Sportes C., Ahmadzadeh M., Fry T.J., Ngo L.T., Schwarz S.L., Stetler-Stevenson M., Morton K.E., Mavroukakis S.A., Morre M., Buffet R., Mackall C.L., and Gress R.E. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 29 (2006) 313-319
42. Sportes C., Hakim F.T., Memon S.A., Zhang H., Chua K.S., Brown M.R., Fleisher T.A., Krumlauf M.C., Babb R.R., Chow C.K., Fry T.J., Engels J., Buffet R., Morre M., Amato R.J., Venzon D.J., Korngold R., Pecora A., Gress R.E., and Mackall C.L. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 205 (2008) 1701-1714
43. Park J.H., Yu Q., Erman B., Appelbaum J.S., Montoya-Durango D., Grimes H.L., and Singer A. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 21 (2004) 289-302
44. Smithgall M.D., Wong J.G., Critchett K.E., and Haffar O.K. IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. J. Immunol. 156 (1996) 2324-2330
45. Gattinoni L., Klebanoff C.A., Palmer D.C., Wrzesinski C., Kerstann K., Yu Z., Finkelstein S.E., Theoret M.R., Rosenberg S.A., and Restifo N.P. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest 115 (2005) 1616-1626
46. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., Matsuki N., Charrier K., Sedger L., Willis C.R., Brasel K., Morrissey P.J., Stocking K., Schuh J.C., Joyce S., and Peschon J.J. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191 (2000) 771-780
47. Lodolce J.P., Boone D.L., Chai S., Swain R.E., Dassopoulos T., Trettin S., and Ma A. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9 (1998) 669-676
48. Anderson D.M., Kumaki S., Ahdieh M., Bertles J., Tometsko M., Loomis A., Giri J., Copeland N.G., Gilbert D.J., and Jenkins N.A. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J. Biol. Chem. 270 (1995) 29862-29869
49. Dubois S., Mariner J., Waldmann T.A., and Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17 (2002) 537-547
50. Schluns K.S., Nowak E.C., Cabrera-Hernandez A., Puddington L., Lefrancois L., and Aguila H.L. Distinct cell types control lymphoid subset development by means of IL-15 and IL-15 receptor alpha expression. Proc. Nat. Acad. Sci. U. S. A. 101 (2004) 5616-5621
51. Schluns K.S., Klonowski K.D., and Lefrancois L. Transregulation of memory CD8 T-cell proliferation by IL-15R alpha(+) bone marrow-derived cells. Blood 103 (2004) 988-994
52. Burkett P.R., Koka R., Chien M., Chai S., Chan F., Ma A., and Boone D.L. IL-15R alpha expression on CD8+ T cells is dispensable for T cell memory. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4724-4729
53. Zhang X., Sun S., Hwang I., Tough D.F., and Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8 (1998) 591-599
54. Burkett P.R., Koka R., Chien M., Chai S., Boone D.L., and Ma A. Coordinate expression and trans presentation of interleukin (IL)-15R{alpha} and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J. Exp. Med. 200 (2004) 825-834
55. Sandau M.M., Schluns K.S., Lefrancois L., and Jameson S.C. Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15R alpha by the same cells. J.Immunol. 173 (2004) 6537-6541
56. Bamford R.N., DeFilippis A.P., Azimi N., Kurys G., and Waldmann T.A. The 5′ untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. J. Immunol. 160 (1998) 4418-4426
57. Neely G.G., Robbins S.M., Amankwah E.K., Epelman S., Wong H., Spurrell J.C., Jandu K.K., Zhu W., Fogg D.K., Brown C.B., and Mody C.H. Lipopolysaccharide-stimulated or granulocyte-macrophage colony-stimulating factor-stimulated monocytes rapidly express biologically active IL-15 on their cell surface independent of new protein synthesis. J. Immunol. 167 (2001) 5011-5017
58. Musso T., Calosso L., Zucca M., Millesimo M., Ravarino D., Giovarelli M., Malavasi F., Ponzi A.N., Paus R., and Bulfone-Paus S. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood 93 (1999) 3531-3539
59. Anderson D.M., Johnson L., Glaccum M.B., Copeland N.G., Gilbert D.J., Jenkins N.A., Valentine V., Kirstein M.N., Shapiro D.N., and Morris S.W. Chromosomal assignment and genomic structure of Il15. Genomics 25 (1995) 701-706
60. Klebanoff C.A., Finkelstein S.E., Surman D.R., Lichtman M.K., Gattinoni L., Theoret M.R., Grewal N., Spiess P.J., Antony P.A., Palmer D.C., Tagaya Y., Rosenberg S.A., Waldmann T.A., and Restifo N.P. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1969-1974
61. Rosenberg S.A. Secrecy in medical research. N. Engl. J. Med. 334 (1996) 392-394
62. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6 (2006) 595-601
63. Ozaki K., Kikly K., Michalovich D., Young P.R., and Leonard W.J. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 11439-11444
64. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., Johnston J., Madden K., Xu W., West J., Schrader S., Burkhead S., Heipel M., Brandt C., Kuijper J.L., Kramer J., Conklin D., Presnell S.R., Berry J., Shiota F., Bort S., Hambly K., Mudri S., Clegg C., Moore M., Grant F.J., Lofton-Day C., Gilbert T., Rayond F., Ching A., Yao L., Smith D., Webster P., Whitmore T., Maurer M., Kaushansky K., Holly R.D., and Foster D. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408 (2000) 57-63
65. Ozaki K., Spolski R., Feng C.G., Qi C.F., Cheng J., Sher A., Morse III H.C., Liu C., Schwartzberg P.L., and Leonard W.J. A critical role for IL-21 in regulating immunoglobulin production. Science 298 (2002) 1630-1634
66. Liu S., Lizee G., Lou Y., Liu C., Overwijk W.W., Wang G., and Hwu P. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int. Immunol. 19 (2007) 1213-1221
67. Toomey J.A., Gays F., Foster D., and Brooks C.G. Cytokine requirements for the growth and development of mouse NK cells in vitro. J. Leukoc. Biol. 74 (2003) 233-242
68. Zeng R., Spolski R., Finkelstein S.E., Oh S., Kovanen P.E., Hinrichs C.S., Pise-Masison C.A., Radonovich M.F., Brady J.N., Restifo N.P., Berzofsky J.A., and Leonard W.J. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201 (2005) 139-148
69. Wang G., Tschoi M., Spolski R., Lou Y., Ozaki K., Feng C., Kim G., Leonard W.J., and Hwu P. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63 (2003) 9016-9022
70. Ma H.L., Whitters M.J., Konz R.F., Senices M., Young D.A., Grusby M.J., Collins M., and Dunussi-Joannopoulos K. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J. Immunol. 171 (2003) 608-615
71. Moroz A., Eppolito C., Li Q., Tao J., Clegg C.H., and Shrikant P.A. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol. 173 (2004) 900-909
72. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., Schluns K., Tian Q., Watowich S.S., Jetten A.M., and Dong C. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448 (2007) 480-483
73. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., Oukka M., and Kuchroo V.K. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448 (2007) 484-487
74. Yang H., Antony P.A., Wildhaber B.E., and Teitelbaum D.H. Intestinal intraepithelial lymphocyte gamma delta-T cell-derived keratinocyte growth factor modulates epithelial growth in the mouse. J. Immunol. 172 (2004) 4151-4158
75. Tsuchiya T., Fukuda S., Hamada H., Nakamura A., Kohama Y., Ishikawa H., Tsujikawa K., and Yamamoto H. Role of gamma delta T cells in the inflammatory response of experimental colitis mice. J. Immunol. 171 (2003) 5507-5513
76. Tesselaar K., Xiao Y., Arens R., van Schijndel G.M., Schuurhuis D.H., Mebius R.E., Borst J., and van Lier R.A. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J. Immunol. 170 (2003) 33-40
77. Robertson M.J., Kirkwood J.M., Logan T.F., Koch K.M., Kathman S., Kirby L.C., Bell W.N., Thurmond L.M., Weisenbach J., and Dar M.M. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin. Cancer Res. 14 (2008) 3462-3469
78. Robertson M.J., Mier J.W., Logan T., Atkins M., Koon H., Koch K.M., Kathman S., Pandite L.N., Oei C., Kirby L.C., Jewell R.C., Bell W.N., Thurmond L.M., Weisenbach J., Roberts S., and Dar M.M. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res. 12 (2006) 4265-4273
79. Rubinstein M.P., Kovar M., Purton J.F., Cho J.H., Boyman O., Surh C.D., and Sprent J. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 9166-9171
80. Stoklasek T.A., Schluns K.S., and Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177 (2006) 6072-6080
81. Mortier E., Quemener A., Vusio P., Lorenzen I., Boublik Y., Grotzinger J., Plet A., and Jacques Y. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 × IL-15R alpha fusion proteins. J. Biol. Chem. 281 (2006) 1612-1619
82. Boyman O., Kovar M., Rubinstein M.P., Surh C.D., and Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311 (2006) 1924-1927
83. Kamimura D., and Bevan M.J. Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J. Exp. Med. 204 (2007) 1803-1812
84. Mostbock S., Lutsiak M.E., Milenic D.E., Baidoo K., Schlom J., and Sabzevari H. IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8(+) T cell responses and increases the ratio of effector/memory CD8(+) T cells to regulatory T cells. J. Immunol. 180 (2008) 5118-5129
85. Boyman O., Ramsey C., Kim D.M., Sprent J., and Surh C.D. IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia. J. Immunol. 180 (2008) 7265-7275
86. Lenardo M.J. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 353 (1991) 858-861
87. Mitsuyasu R., Gelman R., Cherng D.W., Landay A., Fahey J., Reichman R., Erice A., Bucy R.P., Kilby J.M., Lederman M.M., Hamilton C.D., Lertora J., White B.L., Tebas P., Duliege A.M., and Pollard R.B. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial-AIDS Clinical Trials Group 328. Arch. Intern. Med. 167 (2007) 597-605
88. Rosenberg S.A., Yang J.C., White D.E., and Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 228 (1998) 307-319
89. Fyfe G.A., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 14 (1996) 2410-2411
90. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., and Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
91. Rosenberg S.A., and Dudley M.E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 101 Suppl 2 (2004) 14639-14645
92. Frederiksen K.S., Lundsgaard D., Freeman J.A., Hughes S.D., Holm T.L., Skrumsager B.K., Petri A., Hansen L.T., McArthur G.A., Davis I.D., and Skak K. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol. Immunother. 57 (2008) 1439-1449
93. Davis I.D., Skrumsager B.K., Cebon J., Nicholaou T., Barlow J.W., Moller N.P., Skak K., Lundsgaard D., Frederiksen K.S., Thygesen P., and McArthur G.A. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res. 13 (2007) 3630-3636
94. Thompson J.A., Curti B.D., Redman B.G., Bhatia S., Weber J.S., Agarwala S.S., Sievers E.L., Hughes S.D., DeVries T.A., and Hausman D.F. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J. Clin. Oncol. 26 (2008) 2034-2039